You may want to look twice at two big Covid-19 studies
A pair of major medical journals are concerned about the validity of two headline-grabbing Covid-19 studies: one that concluded certain heart drugs were safe, and one that found hydroxychloroquine was not.
As STAT’s Matthew Herper and Andrew Joseph report, the scrutiny centers on Surgisphere, a small company that provided hospital data for both studies. Editors from the Lancet and the New England Journal of Medicine, which published studies based on the company’s data, have publicly expressed doubts in Surgisphere’s work, potentially undermining the widely publicized results.
This is particularly key to the story of hydroxychloroquine, a malaria treatment whose potential in Covid-19 has risen from a medical curiosity to a political flashpoint. After the Lancet published that Surgisphere-powered study finding that hydroxychloroquine was associated with higher mortality than placebo, the World Health Organization paused a global trial meant to test the drug’s benefits.
Read more.
As STAT’s Matthew Herper and Andrew Joseph report, the scrutiny centers on Surgisphere, a small company that provided hospital data for both studies. Editors from the Lancet and the New England Journal of Medicine, which published studies based on the company’s data, have publicly expressed doubts in Surgisphere’s work, potentially undermining the widely publicized results.
This is particularly key to the story of hydroxychloroquine, a malaria treatment whose potential in Covid-19 has risen from a medical curiosity to a political flashpoint. After the Lancet published that Surgisphere-powered study finding that hydroxychloroquine was associated with higher mortality than placebo, the World Health Organization paused a global trial meant to test the drug’s benefits.
Read more.
.png)
No hay comentarios:
Publicar un comentario